These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37442487)

  • 1. Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19.
    Palmer ME; Belcher RM; Engeleit A; Wenzler E; Bulman ZP; Benken ST
    Int J Antimicrob Agents; 2023 Sep; 62(3):106920. PubMed ID: 37442487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
    Wenzler E; Bunnell KL; Bleasdale SC; Benken S; Danziger LH; Rodvold KA
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
    Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
    Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C
    Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of baricitinib in critically ill COVID-19 patients.
    Massart N; Fillatre P; Lemaitre F; Mari A; Tron C
    Clin Biochem; 2023 Aug; 118():110601. PubMed ID: 37353137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD.
    Khadzhynov D; Slowinski T; Lieker I; Spies C; Puhlmann B; König T; Uhrig A; Eggers K; Neumayer HH; Traunmüller F; Joukhadar C; Peters H
    Int J Clin Pharmacol Ther; 2011 Nov; 49(11):656-65. PubMed ID: 22011690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis.
    Surovoy YA; Burkin MA; Galvidis IA; Sobolev MA; Rende OC; Tsarenko SV
    Eur J Clin Pharmacol; 2023 Jan; 79(1):79-87. PubMed ID: 36378296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis.
    Garbez N; Mbatchi LC; Maseda E; Luque S; Grau S; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
    Ther Drug Monit; 2021 Dec; 43(6):747-755. PubMed ID: 33560097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.
    Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA
    Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Practice-Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE-01).
    Kalaria SN; Armahizer M; McCarthy P; Badjatia N; Gobburu JV; Gopalakrishnan M
    Clin Transl Sci; 2020 Sep; 13(5):950-959. PubMed ID: 32223067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid.
    Janssen PK; Foudraine NA; Burgers DM; Neef K; le Noble JL
    Ther Drug Monit; 2016 Dec; 38(6):699-705. PubMed ID: 27494946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.
    Mariat C; Venet C; Jehl F; Mwewa S; Lazarevic V; Diconne E; Fonsale N; Carricajo A; Guyomarc'h S; Vermesch R; Aubert G; Bidault R; Bertrand JC; Zeni F
    Crit Care; 2006 Feb; 10(1):R26. PubMed ID: 16507147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
    Boereboom FT; Ververs FF; Blankestijn PJ; Savelkoul TJ; van Dijk A
    Intensive Care Med; 1999 Oct; 25(10):1100-4. PubMed ID: 10551965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.
    Broeker A; Wicha SG; Dorn C; Kratzer A; Schleibinger M; Kees F; Heininger A; Kees MG; Häberle H
    Crit Care; 2018 Dec; 22(1):341. PubMed ID: 30558639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing ceftaroline dosing in critically ill patients undergoing continuous renal replacement therapy.
    Kalaria S; Williford S; Guo D; Shu Y; Medlin C; Li M; Yeung SYA; Ali F; Jean W; Gopalakrishnan M; Heavner M
    Pharmacotherapy; 2021 Feb; 41(2):205-211. PubMed ID: 33438291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, real-world, clinical pharmacokinetic study to inform lacosamide dosing in critically ill patients undergoing continuous venovenous haemofiltration (PADRE-02).
    Kalaria SN; Armahizer M; McCarthy P; Badjatia N; Gobburu JV; Gopalakrishnan M
    Br J Clin Pharmacol; 2021 Nov; 87(11):4375-4385. PubMed ID: 33855736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.